

Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy

Ilya Ayzenberg, MD; Ingo Kleiter, MD; Alexandra Schröder, MD; Kerstin Hellwig, MD; Andrew Chan, MD; Takashi Yamamura, MD; Ralf Gold, MD

Objective: To report first experiences with interleukin 6 receptor inhibition in therapy-resistant neuromyelitis optica (NMO).

Design: Retrospective case series.

Setting: Neurology department at a tertiary referral center.

Patients: Patients with an aggressive course of NMO switched to tocilizumab after failure of anti-CD20 therapy.

Main Outcome Measures: Annualized relapse rate and disability progression measured by the Expanded Disability Status Scale.

Results: We report 3 female patients with a median age of 39 years (range, 26-40 years) and aquaporin 4–positive NMO. All patients had been treated with different

immunosuppressive and immunomodulating agents, followed by 1 to 3 cycles of rituximab. Despite complete CD20-cell depletion during rituximab therapy, the median annualized relapse rate was 3.0 (range, 2.3-3.0) and the median Expanded Disability Status Scale score increased from 5.0 (range, 4.5-7.0) to 6.5 (range, 5.0-7.0). After the switch to tocilizumab (median duration of therapy, 18 months), the median annualized relapse rate decreased to 0.6 (range, 0-1.3). A total of 2 relapses occurred; however, they were mild and there were no changes in clinical disability.

Conclusions: Interleukin 6 receptor–blocking therapy can be effective in therapy-resistant cases of NMO. Larger controlled studies are needed to confirm the efficacy of tocilizumab.

JAMA Neurol. 2013;70(3):394-397. Published online January 28, 2013. doi:10.1001/jamaneuro.2013.1246

NEUROMYELITIS OPTICA (NMO) is a rare, severely disabling autoimmune disease, preferentially affecting optic nerves and the spinal cord, structures highly expressing the target antigen aquaporin 4 (AQP4). Because of the severity of NMO attacks, prophylactic therapy must be started as soon as possible. Therapy response in NMO differs from that in multiple sclerosis; immunomodulatory medications (interferon beta and glatiramer acetate) seem to be not effective and natalizumab appears to even exacerbate disease activity.^{1,2} Several small studies and case report series demonstrated moderate efficacy of a number of immunosuppressive agents.³ More promising results have been shown for B cell–depleting therapy, yet approximately 20% of patients experience relapses despite the complete depletion of B cells.⁴⁻⁶

Recently, specific AQP4-secreting plasmablasts exhibiting a CD19^{int}CD27^{high}

CD38^{high}CD180⁺ phenotype have been described in NMO.⁷ Secretion of AQP4 antibodies by these cells is dependent on interleukin 6 (IL-6), a cytokine also known to be increased in NMO relapses.^{7,8} To evaluate if the IL-6 receptor–blocking antibody tocilizumab (ACTEMRA) could be a new therapeutic option for NMO, we analyzed the clinical course of 3 patients who were switched to tocilizumab after ongoing aggressive disease despite rituximab therapy.

METHODS

PATIENTS

Patients were identified from a cohort of 18 patients with confirmed NMO treated at a tertiary referral center. We searched for patients with aggressive disease who did not respond to rituximab therapy and had been switched to tocilizumab thereafter. Annual relapse rate and progression of disability, scored by the Expanded Disability Status Scale (EDSS), before

Author Affiliations: Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany (Drs Ayzenberg, Kleiter, Schröder, Hellwig, Chan, and Gold); and Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Yamamura).

Table. Patients' Baseline Characteristics and Clinical Course During Rituximab and Tocilizumab Treatment

	Patient No.		
	1	2	3
Baseline characteristics at start of RTX treatment			
Sex	F	F	F
Age, y ^a	40	26	39
Disease duration, y ^a	9.4	8.2	2.5
AQP4 Abs	Positive	Positive	Positive
Previous treatments (duration/relapses) ^b	IFN beta-1b (2003-2006/10); mitoxantrone hydrochloride, 52 mg/m ² (2006-2007/3)	IFN beta-1b (2004-2005/3); IFN beta-1a (2005-2006/1); glatiramer acetate (2006/3); IFN beta-1a (2006-2009/9)	No therapy (2009-2010/2); azathioprine (2010-2011/2)
Total No. of previous relapses/estimated ARR ^a	13/2.6	16/2.7	4/1.7
RTX therapy			
Duration, mo	32	8	4
No. of CD19 cells during the first relapse, /μL	0	1	2
No. of relapses/estimated ARR	6/2.3	2/3.0	1/3.0
Time from first application to the first relapse, d	18	137	40
EDSS score at start of RTX treatment	5.0	4.5	7.0
EDSS score at end of RTX treatment	6.5	5.0	7.0
MRI findings	Enlargement of spinal cord lesions with contrast enhancement	ND	Enlargement of spinal cord lesions with contrast enhancement
TCZ therapy			
Duration, mo	21	18	9
No. of CD19 cells at start of TCZ treatment, /μL	44	4	2
No. of relapses/estimated ARR	1/0.6	0	1/1.3
EDSS score at start of TCZ treatment	6.5	5.0	7.0
EDSS score at the last visit	6.5	4.0	7.0
MRI/time since start of TCZ treatment, mo	No new lesions, no contrast enhancement/12	No new lesions, no contrast enhancement/9	No new lesions, no contrast enhancement/7

Abbreviations: Abs, anti-AQP4 antibodies; AQP4, aquaporin 4; ARR, annualized relapse rate; EDSS, Expanded Disability Status Scale; IFN, interferon; MRI, magnetic resonance imaging; ND, not determined; RTX, rituximab; TCZ, tocilizumab.

^aRelative to start of RTX treatment.

^bTreatments appear in chronological order.

and during rituximab and tocilizumab treatment were analyzed. Routine brain and spinal cord magnetic resonance imaging was evaluated for contrast-enhancing new or enlarged lesions before and during both therapies.

ETHICAL STATEMENT

The presented 3 patients were treated on an individual basis according to internal recommendations. All data were analyzed retrospectively from patient files. All patients gave written informed consent for publication.

RESULTS

DEMOGRAPHIC AND CLINICAL FEATURES

Three female patients were diagnosed with AQP4 antibody-positive NMO (Table). All patients had longitudinal spinal cord lesions (>3 segments) and a history of optic neuritis and transverse myelitis. No intrathecal immunoglobulin synthesis or oligoclonal bands were in the cerebrospinal fluid of any of the 3 patients. No patient

had concomitant autoimmune diseases. Previous long-term therapies included interferon beta-1a and 1b (n=2), glatiramer acetate (n=1), azathioprine (n=1), and mitoxantrone hydrochloride (n=1). All patients had experienced pronounced disease activity (median, 13 relapses; range, 4-16; median annualized relapse rate, 2.6; range, 1.7-2.7; median EDSS score, 5.0; range, 4.5-7.0) prior to receiving rituximab. The median disease duration at initiation of rituximab was 8.2 years (range, 2.5-9.4 years) and the median age was 39 years (range, 26-40 years).

TREATMENT RESPONSE TO RITUXIMAB

Rituximab was administered at a dose of 2000 mg/cycle (1000 mg + 1000 mg, patient 1) or 1500 mg/cycle (500 mg + 1000 mg, patients 2 and 3), with a 2-week interval between infusions. Patients 1 to 3 received rituximab for 32 (3 cycles), 8 (1 cycle), and 4 (1 cycle) months, respectively. Despite complete CD20-cell depletion, patients continued to experience relapses (median, 2; range,




Figure. Relapses before and during treatment with rituximab and tocilizumab. Shown are all relapses from month -72 to +21 (patient 1), +18 (patient 2), and +9 (patient 3), relative to the start of tocilizumab treatment. Bars depict duration of rituximab and tocilizumab treatment. In patient 3, disease manifested 31 months prior to the start of tocilizumab treatment.

1-6), with at least 1 severe relapse, defined by an EDSS score progression of 1.0 or more; the median annualized relapse rate was 3.0 (range, 2.3-3.0) (Table and **Figure**). Interestingly, in 2 patients, relapses occurred shortly after the first application of rituximab (after 18 and 40 days). Magnetic resonance imaging confirmed acute gadolinium-enhancing spinal lesions in patients 1 and 3. The clinical disability progressed in patients 1 and 2 by 1.5 and 0.5 points, respectively, and remained unchanged, with an EDSS score of 7.0, in patient 3.

TREATMENT RESPONSE TO TOCILIZUMAB

Because of ongoing disease activity, patients were further switched to the anti-IL-6 receptor antibody tocilizumab. Tocilizumab was administered at a dose of 6 mg/kg every 6 weeks in patients 1 and 2 and every 4 weeks in patient 3. Duration of tocilizumab therapy was 21, 18, and 9 months in patients 1 to 3, respectively. Patient 2 was relapse-free and demonstrated improvement of her gait and EDSS score from 5.0 to 4.0 (Table and Figure). Two patients experienced a mild relapse without EDSS score progression, clinically presenting as isolated optic neuritis in patient 1 and moderate progression of the pre-existing motor deficit in patient 3. The relapses occurred 3 and 4 months after tocilizumab treatment initiation, respectively. In both cases, deficits were reversible after receiving steroid pulse therapy. After the therapy regimen in patient 1 had been changed from every 6 to every 4 weeks, she was stable for the next 18 months. Compared with rituximab therapy, the median annualized relapse rate decreased from 3.0 (range, 2.3-3.0) to 0.6 (range, 0-1.3). Tocilizumab therapy was ongoing in all 3 patients.

Tocilizumab was well tolerated. There was no serious infection, malignancy, hypersensitivity reaction, or elevation of transaminase levels. Patient 3 experienced urinary tract infection in the fourth month and mild oral mucositis in the seventh month of therapy. Cholesterol lev-

els had been elevated in patients 1 and 3 prior to tocilizumab therapy and demonstrated no significant increase after therapy initiation.

COMMENT

In this case series, we demonstrated the efficacy of the anti-IL-6 receptor antibody tocilizumab in rituximab-refractory, aggressive cases of NMO. The exact mechanism of action of rituximab in NMO remains unknown. Despite complete depletion of CD20⁺ B cells, it spares CD20-negative plasma cells and has only moderate and probably indirect effects on antibody production.^{5,6} Other rituximab effects include monocyte activation and increased synthesis of B-cell activating factor, a key molecule supporting differentiation and survival of B cells as well as immunoglobulin production.^{6,9} In line with this, an early transient increase of AQP4 antibodies after rituximab application has been reported.¹⁰ Notably, in 2 of our patients, relapses occurred early after rituximab initiation.

Inhibition of CD20-negative plasmablasts, which produce pathogenic AQP4 antibodies, might be an alternative treatment strategy. In the presented cases, a switch to tocilizumab led to definite clinical improvement. Recently, another patient successfully treated with tocilizumab was reported by Araki et al.¹¹ They demonstrated a substantial reduction of the frequency of CD19^{int}CD27^{high}CD38^{high}CD18⁻ plasmablasts and titer of anti-AQP4 antibodies within 1 month after tocilizumab initiation. Similarly, tocilizumab decreased the frequency of CD27^{high}CD38^{high}IgD⁻ plasmablasts and the titer of anti-double-stranded DNA antibodies in systemic lupus erythematosus as well as titers of rheumatoid factor in patients with rheumatoid arthritis.¹²

Despite overall clinical stabilization, mild relapses occurred in 2 of our patients as well as in the Araki et al case.¹¹ In patient 1, we reduced the application intervals from every 6 to 4 weeks and the patient was relapse-free afterward. Accordingly, an escalation study demonstrated further clinical improvement in rheumatoid arthritis after dose escalation from 4 to 8 mg/kg.¹³

As demonstrated in rheumatoid arthritis, tocilizumab has a good safety and tolerability profile. Infections are the most common adverse events; however, rates of serious infections remain low at least for 5 years, demonstrating safety of continuous tocilizumab therapy.¹³ Possible tuberculosis reactivation and opportunistic infections make careful observations essential. Importantly, C-reactive protein is directly downregulated by tocilizumab and cannot be used as a sensitive diagnostic marker. In our patients, no serious adverse events were observed. Reported urinary tract infection and mild oral mucositis have been treated on an ambulatory basis without any complications.

We propose that IL-6 receptor blockade with tocilizumab is a promising therapeutic option for aggressive, therapy-resistant cases of NMO. Larger controlled studies with longer follow-up periods are needed to confirm the efficacy, safety, and optimal responders for tocilizumab in NMO.

Accepted for Publication: October 4, 2012.

Published Online: January 28, 2013. doi:10.1001/jamaneurol.2013.1246

Correspondence: Ingo Kleiter, MD, Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, 44791 Bochum, Germany (ingo.kleiter@rub.de).

Author Contributions: *Study concept and design:* Kleiter, Chan, and Gold. *Acquisition of data:* Ayzenberg, Kleiter, Schröder, Hellwig, and Chan. *Analysis and interpretation of data:* Ayzenberg, Kleiter, Chan, and Yamamura. *Drafting of the manuscript:* Ayzenberg and Kleiter. *Critical revision of the manuscript for important intellectual content:* Ayzenberg, Kleiter, Schröder, Hellwig, Chan, Yamamura, and Gold. *Administrative, technical, and material support:* Hellwig, Chan, and Gold. *Study supervision:* Kleiter and Gold.

Conflict of Interest Disclosures: Dr Kleiter reports receiving travel reimbursements and speaker and consulting honoraria from Bayer HealthCare, Biogen Idec, Merck Serono, and Novartis as well as research support from Bayer HealthCare, Novartis, and Biogen Idec. Dr Hellwig reports research support from Biogen Idec, Bayer HealthCare, Merck Serono, sanofi-aventis, and Novartis Pharma as well as speaker honoraria from Biogen Idec, Bayer HealthCare, Merck Serono, sanofi-aventis, and Novartis Pharma. Dr Chan received speaker and consulting honoraria and scientific grant support from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis Pharma, and Teva Pharma. Dr Gold received speaker and consulting honoraria and scientific grant support from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis Pharma, Chugai Pharmaceuticals, Teva Pharma, and Genzyme.

Funding/Support: This work was supported by grants from the German Ministry for Education and Research ("German Competence Network Multiple Sclerosis") (Dr Gold).

REFERENCES

1. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. *Mult Scler*. 2007;13(2):256-259.
2. Kleiter I, Hellwig K, Berthele A, et al; Neuromyelitis Optica Study Group. Failure of natalizumab to prevent relapses in neuromyelitis optica. *Arch Neurol*. 2012; 69(2):239-245.
3. Morrow MJ, Wingerchuk D. Neuromyelitis optica. *J Neuroophthalmol*. 2012;32 (2):154-166.
4. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. *Arch Neurol*. 2008;65(11): 1443-1448.
5. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. *Arch Neurol*. 2011;68(11):1412-1420.
6. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. *Neurology*. 2011; 76(15):1310-1315.
7. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. *Proc Natl Acad Sci U S A*. 2011;108(9):3701-3706.
8. Içöz S, Tüzün E, Kürtüncü M, et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. *Int J Neurosci*. 2010;120(1): 71-75.
9. Lehmann-Horn K, Schleich E, Hertenberg D, et al. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. *J Neuroinflammation*. 2011;8(8):146.
10. Nakashima I, Takahashi T, Cree BA, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. *J Clin Neurosci*. 2011; 18(7):997-998.
11. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab [published online July 11, 2012]. *Mod Rheumatol*. doi:10.1007/s10165-012-0715-9.
12. Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus [published online August 2, 2012]. *Ann Rheum Dis*. doi:10.1136/annrheumdis-2012-201310.
13. Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. *Clin Med Insights Arthritis Musculoskelet Disord*. 2012;5:27-42.

A Trifluoromethyl Analogue of Celecoxib Exerts Beneficial Effects in Neuroinflammation

Alessandra Di Penta^{1,2}, Asako Chiba^{3,4}, Iraide Alloza^{1,2,5}, Ane Wyssenbach⁶, Takashi Yamamura³, Pablo Villoslada⁷, Sachiko Miyake^{3,4}, Koen Vandenbroeck^{1,2,5*}

1 Neurogenomiks Laboratory, University of Basque Country (UPV/ EHU), Zamudio, Spain, **2** Achucarro Basque Center for Neuroscience, Zamudio, Spain, **3** Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan, **4** Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, **5** IKERBASQUE, Basque Foundation for Science, Bilbao, Spain, **6** Neurotek Laboratory, University of Basque Country (UPV/EHU), Zamudio, Spain, **7** Center of Neuroimmunology, Institute of Biomedical Research August Pi Sunyer (IDIBAPS) – Hospital Clinic of Barcelona, Barcelona, Spain

Abstract

Celecoxib is a selective cyclooxygenase-2 (COX2) inhibitor. We have previously shown that celecoxib inhibits experimental autoimmune encephalomyelitis (EAE) in COX-2-deficient mice, suggestive for a mode of action involving COX2-independent pathways. In the present study, we tested the effect of a trifluoromethyl analogue of celecoxib (TFM-C) with 205-fold lower COX-2 inhibitory activity in two models of neuroinflammation, i.e. cerebellar organotypic cultures challenged with LPS and the EAE mouse model for multiple sclerosis. TFM-C inhibited secretion of IL-1 β , IL-12 and IL-17, enhanced that of TNF- α and RANTES, reduced neuronal axonal damage and protected from oxidative stress in the organotypic model. TFM-C blocked TNF- α release in microglial cells through a process involving intracellular retention, but induced TNF- α secretion in primary astrocyte cultures. Finally, we demonstrate that TFM-C and celecoxib ameliorated EAE with equal potency. This coincided with reduced secretion of IL-17 and IFN- γ by MOG-reactive T-cells and of IL-23 and inflammatory cytokines by bone marrow-derived dendritic cells. Our study reveals that non-coxib analogues of celecoxib may have translational value in the treatment of neuro-inflammatory conditions.

Citation: Di Penta A, Chiba A, Alloza I, Wyssenbach A, Yamamura T, et al. (2013) A Trifluoromethyl Analogue of Celecoxib Exerts Beneficial Effects in Neuroinflammation. PLoS ONE 8(12): e83119. doi:10.1371/journal.pone.0083119

Editor: Giovambattista Pani, Catholic University Medical School, Italy

Received: June 14, 2013; **Accepted:** October 31, 2013; **Published:** December 11, 2013

Copyright: © 2013 di Penta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by Grant Grupos de Investigación (UPV/EHU; ref. IT512-10) to KV; Ministerio de Ciencia e Innovación (MICINN, Madrid, Spain; ref. SAF2008-00433 and SAF2012-32118) and by the Gobierno Vasco's SAIOTEK Program (ref. 'ERtek' S-PE09UN33) to KV; Instituto de Salud Carlos III: FIS PI041445 (MIOTRED) to PV; Juan de la Cierva program of the Ministerio de Ciencia e Innovación (MICINN, ref. JCI-2009-04462) to AdP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors declare that Pablo Villoslada, as one of the co-authors of the manuscript, is a PLOS ONE Editorial Board. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: k.vandenbroeck@ikerbasque.org

☯ These authors contributed equally to this work.

Introduction

Nonsteroidal anti-inflammatory drugs are indicated for the treatment of a variety of chronic inflammatory diseases and act by inhibiting prostaglandin H synthase (also known as cyclooxygenase, COX). Two forms of this enzyme are known: COX1 that is expressed constitutively in most tissues and plays a role in the protection of the gastrointestinal mucosa, renal hemodynamics, and platelet thrombogenesis, and COX2 that is inducible and expressed in cells involved in inflammation [1]. Selective COX2 inhibitors (i.e., celecoxib, rofecoxib, and valdecoxib) have been developed for the treatment of inflammatory diseases [2] minimizing gastrointestinal adverse reactions caused by COX-1 inhibition.

Celecoxib has been demonstrated to act via both COX2-dependent and -independent pathways, both associated with potent anti-tumour effects [3,4]. Recently, we have shown that both celecoxib and its trifluoromethyl analogue, TFM-C (4-[5-(4-trifluoromethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) that displays 205-fold lower COX2-inhibitory activity, can inhibit secretion of (hetero)dimeric cytokines belonging to the interleukin-12 (IL-12) family (including IL-23 and p40 homodimers) with similar IC₅₀'s. Using recombinant cell lines, TFM-C caused Ca²⁺-dependent chaperone-mediated cytokine subunit retention in the endoplasmic reticulum (ER) coupled to degradation via the ER stress protein HERP [5,6]. This observation provided a translational extension of recent findings in our lab of functional chaperone interaction peptide motifs conserved in cytokines as

well as of multiple ATP-dependent cytokine-chaperone interactions during ER transit of cytokines [7-9]. Perturbance of ER Ca²⁺ by celecoxib and non-coxib analogues triggers a cellular response known as “unfolded protein response” (UPR) [4,10,11]. The UPR has a dual role in the cell survival: in normal conditions works as a pro-survival response mediated by the blockage of protein translation and activation of transcription factors that can restore the ER function to its normal physiological state. However, if ER stress persists, its pro-survival function can switch to a pro-apoptotic program, finally leading to cell death [12,13].

COX-2 inhibitors such as indomethacin or rofecoxib exert beneficial effects in EAE; the latter, for example, by modulating Th1/Th2 responses [14,15]. Recently, we have shown that celecoxib inhibits EAE [16]. In particular, we found that celecoxib in contrast to other COX-2 inhibitors such as nimesulid, prevented EAE by inhibiting the infiltration of inflammatory cells into the central nervous system, MOG-specific Th1 cytokine production and expression of adhesion molecules and MCP-1 [16]. This protective effect was not mediated via COX2 inhibition since it was also observed in COX2-deficient mice [16]. We have demonstrated that celecoxib and its analogue TFM-C exerted beneficial effects in two models of arthritis: collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA). In particular, TFM-C, more so than celecoxib, inhibited the severity of CIA and CAIA by suppressing the activation of mast cells and the production of inflammatory cytokines by macrophages [17]. Nevertheless, celecoxib and other COX2 inhibitors display adverse effects that may compromise further implementation in clinical practice. Increased risk for myocardial infarction and stroke in drug recipients have been reported [18-22]. Comparison of cardiovascular risks profiles of celecoxib vs the non-selective nonsteroidal anti-inflammatory drug naproxen and ibuprofen is currently addressed in the PRECISION trial (<http://clinicaltrials.gov/show/NCT00346216>). Suppression of prostacyclin (PGI2) and prostaglandin E2, two COX-2-derived products, may provide protective constraint mechanisms on processes such as thrombogenesis and atherogenesis [23]. In rodents, celecoxib predisposes to platelet activation and arterial thrombosis by suppressing PGI2 [24]. Similarly, selective inhibition of COX-2 can enhance platelet–vessel wall interactions and platelet adhesion *in vivo* increasing the risk of thrombosis [25].

We hypothesized that TFM-C may constitute a new drug candidate that retains the beneficial effects of celecoxib in the EAE model while its much decreased COX2 inhibitory activity would render it less adverse in terms of cardiovascular risk. In this study, we have analyzed the effect of TFM-C on cytokine secretion, demyelination, and axonal damage in mice cerebellar organotypic cultures, a model of neuroinflammation, and assessed its activity in the EAE model.

Materials and Methods

Ethics statement

Animals were handled in accordance with the European Communities Council Directive (Directive 2010/63/EU), the

Table 1. List of primary antibodies used for immunofluorescence (IF) and western blot (WB) studies.

Antigen	Description	Dilution	Company
ARMET	ARMET antibody, Rabbit	1:2000 (WB)	AbCam
HERP	Homocysteine-induced	1:200/1:400 (IF)	Hirabayashi Y [6].
	endoplasmic reticulum protein, Mouse	1:2000 (WB)	
Iba1	Ionized calcium binding adaptor molecule 1: anti-Iba 1, Rabbit	1:400/1:500 (IF)	Wako
iNOS	Inducible nitric oxide synthase: purified rabbit anti-iNOS/NOS type II	1:200 (IF) 1:500 (WB)	BD Bioscience
LC3B	LC3B (D11) XP™ Rabbit mAb	1:1000 (WB)	Cell Signaling
MBP	Myelin Basic Protein; Rat anti-MBP (82-87) antibody	1:200 (IF)	Serotec
NFH	Neurofilament heavy (phosphorylated and non-phosphorylated NFH): rabbit polyclonal antiserum against the 200 kD Neurofilament Heavy	1:200 (IF)	AbCam
NFL	Neurofilament light C28E10, Rabbit mAb	1:200 (IF)	Cell Signaling
PARK2	Rabbit polyclonal to Parkin	1:750 (WB)	AbCam
RAB24	Purified Mouse Anti-Rab24	1:1000 (WB)	BD Bioscience
SMI32	non-phosphorylated neurofilament heavy SMI32, Mouse	1:200 (IF)	Stenberg
TNF-α	Anti-Murine TNF-alpha, Rabbit	1:300 (IF)	MBL
Tubulin	α-Tubulin Antibody [HRP], mAb, Mouse	1:2000	GenScript

doi: 10.1371/journal.pone.0083119.t001

Spanish regulations for the procurement and care of experimental animals (RD 53/2013, February 1st), and the study was approved by the Ethical Committee on Animal Research of the University of Basque Country (UPV/EHU). EAE experiments were approved by the Institutional Animal Care and Use Committee of the National Institute of Neuroscience (Tokyo, Japan).

Materials and animals

All animal experiments in this study were performed using C57BL/6J mice (Harlan Laboratories, Italy). C57BL/6J Jcl mice used in EAE experiments were purchased from CLEA Japan, Inc. Mice were maintained in a temperature-controlled environment with food and water *ad libitum* at 12-hour light/12-hour dark cycle. The animals used in this study were 8 weeks old for EAE experiments and 8 days old for cerebellar organotypic cultures experiments. TFM-C was synthesized by Onyx Scientific (Sunderland, UK). All antibodies used in this work are indicated in Table 1.

Induction and clinical assessment of EAE

C57BL/6J Jcl (B6) female mice (n = 5-6 per group, 7-8 weeks old) were immunized subcutaneously at the base of the tail with 100 µg of myelin oligodendrocyte glycoprotein 35-55

(MOG35-55) peptide (amino acid sequence, MEVGWYRSPFSRVVHYYRNGK, derived from mouse MOG) dissolved in 0.1 ml phosphate buffered saline (PBS) and 0.1 ml CFA containing 1 mg of *Mycobacterium tuberculosis* strain H37Ra (*Mtb* H37Ra). Shortly after immunization and 48 h later, the mice were injected i.p. with 200 ng of *Bordetella pertussis* toxin (List Biological Laboratories). Mice were randomly assigned to three treatment groups receiving intraperitoneal injections of TFM-C or celecoxib at doses of 10 µg/g, or control vehicle every other day from the day of immunization. In the control group, the sample size is n=5-6 per group (16 animals in total) and in the TFM-C-treated group n=4-5 animals per group (14 animals in total). The experiment was repeated three times in order to respect the directives for reduction of the number of animals in animal experiments. Only 5 animals were used in the celecoxib-treated group because we have assessed the effect of celecoxib in a previous study [16]. Clinical scores of EAE were assigned daily as follows: 0 = normal; 1 = weakness of the tail and/or paralysis of the distal half of the tail; 2 = loss of tail tonicity; 3 = partial hind limb paralysis; 4 = complete hind limb paralysis; 5 = forelimb paralysis or moribund; 6 = death. The EAE scoring was conducted by personnel unaware of treatment-group assignments. Mice were sacrificed with lethal dose of diethyl ether.

Cerebellar organotypic cultures

The cerebellar slice culture was based on published protocols [26,27]. Organotypic slice cultures were prepared from 8-day old C57BL/6 mice. Cerebella were cut at 350 µm with a McIlwain Tissue Chopper (The Mickle Laboratory Engineering Co. LTD.) and three slices were plated on Millicell-CM culture inserts. From 10 mice we obtained approximately 90 slices. Cultures were incubated at 37°C and 5% CO₂ in 50 % basal medium with Earle's salt, 25% Hank's buffered salt solution, 25% inactivated horse serum, 5mg/ml glucose, 0,25mM L-glutamine and 25µg/ml Pen/Strep (Invitrogen). Cerebellar slices were maintained in culture for 7 days and then pre-treated with 50 µM of TFM-C for 2 hours followed by stimulation with 15 µg/ml of lipopolysaccharide (LPS; Sigma L4391) for 6 and 24 hours, or as indicated.

BV2 cell line

BV2 cells were provided by Prof. Carlos Matute (University of the Basque Country, Leioa, Spain) [28] and were maintained in Dulbecco's Modified Eagle's medium (DMEM) containing 5% heat inactivated Fetal Bovine Serum (FBS), 4 mM L-Glutamine (SAFC biosciences), 20 mM Hepes (Sigma) and 25µg/ml Pen/Strep (Invitrogen) antibiotics at 37°C in a humidified chamber with 5% CO₂. Before treatment, cells were washed twice with DMEM, then pre-incubated with TFM-C (30 µM or 50 µM) for 2 hours and stimulated with 1 µg/ml LPS (Sigma L4391) for 3, 6, 12 and 24 hours.

HEK-293 cell line and PCR arrays

Human embryonic kidney-293 cells (HEK-293; Invitrogen), were cultured in DMEM (Sigma) supplemented with 10 % fetal bovine serum (Sigma), 2 mM L-glutamine (Invitrogen) and

25µg/ml Pen/Strep (Invitrogen). Cells were washed twice with DMEM and incubated with TFM-C (50 µM) for 3, 6, 12 and 24 hours. RNA was extracted and reverse transcribed using RT² First Strand Kits (SABiosciences, address), followed by profiling of the expression of 84 key genes each belonging to UPR, Ubiquitination and Autophagy Pathway RT² Profiler PCR Arrays (SABiosciences, address). Data was analyzed using the manufacturer's PCR Array Data Analysis Software.

Total protein extraction and Western Blot

Three cerebellar slices, HEK-293 and BV2 cells were homogenised by stroke dounce homogenization in 60 µl of ice-cold RIPA buffer (150mM NaCl; 50mM Tris-Cl, pH 7.5; 1% NP-40; 0.5% DOC; 0.1% SDS) and the lysate was centrifuged at 15.000 x g for 10 min at 4°C. Total protein concentration was estimated by the Bradford assay (Bio-Rad). 10 µg of total protein from cerebellar slices, BV2 or HEK-293 cells were separated by SDS-PAGE on Bio-Rad TGX Stain-Free precast gels. The gels were exposed to UV irradiation for 5 min and then total protein was transferred onto a nitrocellulose membrane (Bio-Rad). UV irradiation activates a covalent reaction between the trihalocompound and tryptophan residues on the proteins in the gel, resulting in UV induced fluorescence (Figure S5). Total protein was visualized with ChemiDoc (Bio-Rad) and quantified using Image Lab 4.0 software. The filters were pre-wetted in blocking buffer (5% dried non-fat milk or 2% casein, 20 mM Tris pH 8, 300 mM NaCl, 0.1% Tween-20) and then hybridized for 2h or O.N. with primary antibodies in blocking buffer (Table 1); the secondary antibodies (HRP-conjugated anti-mouse or anti-rabbit from Cell Signaling) were used at a dilution of 1:2000.

RNA isolation and Quantitative RT-PCR (QPCR)

Cerebellar organotypic cultures, HEK-293 and BV2 cells were lysed with TRI reagent (Sigma). Chloroform was added for phase separation with RNA remaining in the aqueous phase. RNA was precipitated with 2-propanol and the pellet resuspended in DNA/RNA free water (Invitrogen). RNA was quantified using Nanodrop 2000c spectrophotometer (Thermo Scientific). 200 ng of mice organotypic cultures, HEK-293 and BV2 cells RNA were reverse-transcribed to cDNA using random primers according to manufacturer's protocol (Applied biosystems). QPCR was performed with the Supermix for SsoFast EvaGreen (Biorad) on a 7500 Fast Real-Time PCR System (Applied Biosystems). For each target gene, QPCR QuantiTect Primer Assay were used (Qiagen). Expression levels for the transcripts of interest were normalized to that of endogenous glyceraldehyde 3-phosphate dehydrogenase or hypoxanthine phosphoribosyltransferase 1 (Hprt1). The data were calculated as percentage fold expression or $2^{-\Delta\Delta Ct}$ relative to the average of the untreated control group, unless indicated otherwise.

Quansys Q-Plex™ Array Chemiluminescent and ELISA

For Q-Plex system analysis, 30 µl of medium from mice cerebellar organotypic cultures treated with LPS or LPS/TFM-C were used. Mouse Cytokine Stripwells (16-plex) were used following the manufacturer's instructions (Quansys Bioscience).

The chemiluminescent signal was acquired with Bio-Rad ChemiDoc camera and the image was analyzed with Q-View Software (Quansys Bioscience). BV2 cells were pre-treated with TFM-C (30 μ M or 50 μ M) for 2 hours and then stimulated with LPS for different periods of time (0, 3, 6, 12 and 24 hours) and the culture supernatants were collected to quantify the secreted IL-1 β , tumor necrosis factor (TNF- α) and IL-6. Mouse ELISA Kits were used according to the manufacturer's instructions (eBioscience, BD Bioscience, R&D Systems).

Immunofluorescence microscopy

Cerebellar slices were fixed with 4% paraformaldehyde (PFA) for 40 min, washed with PBS for 10 min, and blocked at RT for 2 hours in 10% normal goat serum (NGS; Vector Laboratories) and 0.5% Triton X-100 in PBS. The slices were incubated overnight at 4°C with the distinct primary antibodies (Table 1) in blocking solution (10% NGS and 0.3% Triton X-100 in PBS). The slices were washed and incubated in blocking solution containing the secondary antibody mixture and washed three times with 0.1% Triton X-100 in PBS. BV2 cells were fixed with 4% PFA for 20 min, washed with PBS for 10 min, permeabilized for 20 min with 0.2% Triton X-100 in PBS and blocked at RT for 30 min in 10% FBS (Invitrogen) in PBS. The cells were incubated 1 hour with the Iba1 and HERP (1:400; kindly supplied by Dr. Yasuhiko Hirabayashi, Tohoku University, Japan) or TNF- α primary antibodies in blocking solution (10% FBS in PBS). After washing, the cells were incubated in blocking solution containing the secondary antibody mixture, washed three times with PBS and incubated with DAPI (1:50000; Molecular Probes) in PBS. The secondary antibodies used were mouse IgG Cy2-linked, rabbit IgG Cy3-linked (from goat, 1:200; GE Healthcare) and goat anti-rat IgG Alexa Fluor 488 (1:200; Molecular Probes). The slices and coverslips were mounted in Gel/Mount anti-fading mounting medium (Biomedex) and pictures were captured by confocal scanning microscopy (Olympus Fluoview FV500) from single images all through the whole tissue or cells (but avoiding the surface of the culture in contact with air).

DAPI and Propidium iodide (PI) staining

12 hours before LPS/TFM-C (3, 6, 12 and 24 hours) treatment BV2 cells were incubated over night with PI (250 ng/ml; Fluka) and then fixed with 4% PFA. The cells were washed three times with PBS and then incubated with DAPI (1:50000; Molecular Probes) in PBS. Coverslips were embedded in Fuoro-Gel (Electron Microscopy Science). Images were recorded using the confocal microscope and analyzed using the ImageJ program (version 1.40).

Flow cytometry of BV2 cells

The expression of intracellular TNF- α was evaluated by cytofluorometry. 1×10^6 cells were plated and after 24 hours treated with LPS (1 μ g/ml) or pre-treated with TFM-C for 2 hour and then stimulated with LPS/TFM-C for 3, 6, and 24 hours. The cells were detached with trypsin, washed in PBS, pelleted at 300 g for 10 min and fixed with PFA 2% for 20 min. Then, cells were permeabilized with 0.2% Triton in PBS for 20 min, blocked with 10% NGS in PBS for half hour, and incubated with

primary antibody TNF- α (1:100; MBL) for 1 hour in blocking solution. After washing, cells were incubated with secondary antibody (1:500 goat anti-mouse AlexaFluo 488; LifeTechnology) in blocking solution for 30 min in darkness. Following further washes, cells were pelleted and the fluorescence was analyzed using a Gallios cytometer (Beckman Coulter) at excitation/emission wavelengths of 488/515-535 nm.

Astrocyte-enriched cell culture

Primary cultures of cerebral cortical astrocytes were prepared as described previously by McCarthy and de Vellis (1980) [29]. Briefly, forebrains were removed from the skulls, the meninges were carefully excised under a dissecting microscope, and the cortices were isolated. Tissue was incubated for 15 min in Hank's Balanced Salt Solution (HBSS) with trypsin and DNAase, the reaction was stopped with DMEM supplemented with 10% FBS and centrifuged to remove cellular debris. Cells were resuspended in Iscove's Modified Dulbecco's Medium supplemented with 10% FBS and antibiotic/antimycotic solution, and the cells were dissociated by passage through needles of decreasing diameter (21 G and 23 G) 10 times. Cells were re-centrifuged and then resuspended in Iscove's Modified Dulbecco's Medium supplemented with 10% FBS and antibiotic/antimycotic solution. Cells were seeded into poly-D-lysine-coated flasks, and maintained in culture at 37°C and 5% CO₂. The culture medium was renewed the day after seeding, and twice a week thereafter. After 8 days, cultures were shaken (3 hours, 350 rpm) to deplete microglial cells and were trypsinized and plated onto poly-D-lysine-coated, 24-well plates.

Statistical analysis

All experiments were performed at least three times, and control cultures were time-matched with testing cultures. The values were expressed as the means $\pm$ SEM. ANOVA or Student's t-tests were used to determine statistical significance, as indicated, and all analyses were performed using SPSS 15.0 software (IBM). EAE clinical or pathological scores for the group of mice are presented as the mean group clinical score $\pm$ SEM, and statistical differences were analyzed with a non-parametric Mann-Whitney U-test.

Results

TFM-C modulates cytokine release and suppresses oxidative stress and axonal damage in mouse cerebellar organotypic cultures

The effect of TFM-C on cytokine release was assessed in a model of neuroinflammation consisting of mice cerebellar organotypic cultures stimulated with LPS, by means of a multiplex ELISA-based Q-Plex assay system (see Materials and Methods). Of 16 assessed cytokines, 5 were identified of which LPS-induced secretion was modulated by TFM-C (Figure 1A). While LPS challenge induced varying levels of the pro-inflammatory cytokines IL-1 α , IL-1 β , IL-3, IL-5, IL-6, IL-10, IL-12, IL-17, MCP-1, IFN- γ , TNF- α , MIP-1 α and RANTES

(Figure 1A), TFM-C treatment significantly decreased IL-1 β , IL-12 and IL-17 release and increased TNF- α and RANTES. mRNA levels of a subset of these cytokines were also measured in mice organotypic cultures treated with LPS or LPS/TFM-C. HERP was included as a marker for ER stress that is inducible by TFM-C [6,9]. TFM-C treatment decreased IL-1 β mRNA expression levels at 6 and 24 hours, but those of IL-6 and IL-10 only at 24 hours (Figure 1B). In contrast, TNF- α mRNA levels were significantly higher after 6 hours of TFM-C treatment and this trend persisted at the 24 h time-point (non-significant). This mirrored the increased levels of secreted TNF- α demonstrated in Figure 1A. No significant changes were observed for IL-12p35, IL-23p19 and HERP mRNAs.

Next we scored the effect of TFM-C on LPS-induced oxidative stress, demyelination and axonal damage in the organotypic model [30–33] using immunofluorescence, immunoblot and QPCR. The analyzed markers included iNOS for oxidative stress, CNPase for demyelination, SMI32 for axonal damage, and HERP for ER stress. Immunofluorescence showed that TFM-C increased HERP protein expression in microglia identified with Iba1, and upregulated HERP protein in the total culture (Figure 2A, panel a; Figure 2B). Axonal damage was visualized by dual immunostaining for both total (phosphorylated and non-phosphorylated) NFH and non-phosphorylated NFH (SMI32; Figure 2A, panel d). In response to LPS, non-phosphorylated NFH was found to accumulate at 3.5 higher levels compared to total NFH, suggestive for induction of axonal dysfunction. Furthermore, LPS-induced axonal damage was visible via formation of swollen structures (beading and spheroids; white box in Figure 2A, panel d) associated with impaired axonal transport and transection [34]. TFM-C prevented formation of swollen structures and maintained LPS-induced non-phosphorylated neurofilament levels to those of baseline control (Figure 2D). In contrast, TFM-C treatment had no effect on demyelination assessed by MBP/NFL immunofluorescence (Figure 2A, panel c) or CNPase expression (Figure 2B). Finally, pretreatment with TFM-C prior to LPS challenge strongly reduced iNOS expression determined by immunofluorescence, Western Blot and QPCR (Figure 2A, panel b; Figure 2B & C). TFM-C did not affect expression of MHCII (Figure S1). Taken together, these results indicate that TFM-C partially counteracted LPS-induced effects reminiscent of an anti-inflammatory, anti-oxidant and neuroprotective mode of action.

TFM-C suppresses cytokine release and induces UPR / ER stress in BV2 microglia cells

Previously, we have demonstrated that TFM-C inhibits secretion of the (hetero)dimeric IL-12 family cytokines IL-12, p40₂ and IL-23 through a Ca²⁺-dependent mechanism involving chaperone-mediated cytokine retention in the ER coupled to degradation via HERP protein, and that TFM-C dramatically upregulates *HERP* gene expression in various cell lines [5,6,9]. In organotypic cultures, virtually no effect was seen on mRNA production of *HERP* at 6 and 12 hours of LPS/TFM-C treatment in compared with LPS stimulation (Figure 1B). To verify whether TFM-C is capable of inducing ER stress in microglia, the mouse microglial BV2 cell line was used. Specifically, we

measured mRNA of *HERP* and IL-23p19, both of which are induced by ER stress [5,6,35]. BV2 cells were pre-treated with TFM-C (30 and 50 μ M) for 2 hours and then stimulated with LPS for 3, 6, 12 and 24 hours in the presence or absence of TFM-C, which showed significant dose-dependent up-regulation of IL-23p19 and *HERP* (Figure 3B). Figure 3C shows that co-treatment of LPS with TFM-C led to increased accumulation of *HERP* in microglial cells (Figure 3C, panel a). In immunoblot, *HERP* protein levels were increased in BV2 cells at 12 hours of treatment in the presence of 50 μ M of TFM-C plus LPS compared to LPS-only challenge (Figure 3C, panels b and c; Figure S5). To answer the question whether TFM-C is also able to block cytokine release from BV2 cells, IL-1 β , IL-6 and TNF- α mRNA and secreted protein levels were analyzed (Figure 3A). TFM-C significantly decreased LPS-induced IL-1 β mRNA and protein secretion starting at 6 hours of treatment. However, TFM-C exerted biphasic opposing effects on TNF- α mRNA levels at 3 (decrease) versus 24 (increase) hours compared to LPS-only challenge; of note, TFM-C suppressed secreted TNF- α protein levels throughout the duration of the experiment. For IL-6, no significant changes were observed in mRNA levels while the secreted protein was down-regulated at 12 hours of TFM-C treatment. To rule out occurrence of apoptotic cell death as contributing factor in suppression of cytokine secretion, cells were stained with DAPI and PI which is only incorporated by cells that have suffered membrane damage. TFM-C/LPS treatment decreased cell viability with approximately 4%, similar to LPS-only treated cells (Figure 3D). To identify additional UPR/ER stress-regulated genes potentially involved in altered cytokine folding/assembly/secretion, the effect of TFM-C on transcription of 252 genes belonging to UPR, autophagy and ubiquitination pathways was analyzed in HEK-293 cells (Figure S2A). We identified 36 genes with a fold increase > 2.5 and confirmed *HERP* as the gene showing the fifth highest degree of upregulation by TFM-C (fold increase of 9.1 in the UPR PCR Arrays). *DDIT3* (CHOP), a primordial ER stress response gene [13,36], was identified with some distance as the gene showing the highest degree of induction by TFM-C (36-fold). Further analysis of the kinetics of upregulation by TFM-C of 5 of these genes, *PARK2*, *ARMET*, *FBXO4*, *RAB24* and *MAP1LC3B*, in addition to *HERP*, was performed in both HEK-293 and BV2 cells (Figure S2B and S2C). At the protein level, only *HERP*, *MAP1LC3B* and *ARMET* showed clear changes in the kinetics of their production in HEK-293 cells. In BV2 cells, TFM-C significantly decreased *PARK2* expression at 3 and 12 hours, and increased *RAB24* expression at 3 hours both compared with LPS-treated cells. No modification in *MAP1LC3B* and *ARMET* protein expression was observed (Figure S2D). Thus, TFM-C induces a gene expression signature predominantly enriched for UPR/ER stress response and ubiquitination pathway genes, including to a lesser extent also some genes involved in autophagy (Figure S2A). Pending mechanistic studies, this suggests that its suppressive effect on cytokine secretion may be functionally related to alterations in protein transit and turnover pathways, as suggested in our previous work [5,6,9,17].




Figure 1. Effect of TFM-C on cytokine production in organotypic cerebellar cultures. A) After 7 DIV organotypic cultures were treated with TFM-C (50μM) for 6h and then stimulated with 15μg/ml LPS for 24h in presence of TFM-C. Panel a) Lay-out of cytokine-specific antibody spots in the 16-plex cytokine Stripwell array (left image) and visualization of cytokine-specific chemiluminescence in culture medium of LPS-treated organotypic cultures in the absence or presence of TFM-C (right images). Cytokine levels significantly affected by TFM-C are highlighted in grey. Panel b) pg/ml of cytokines were indicated. sd: standard deviation. ND: not determinable. B) Effect of TFM-C on IL-1β, IL-6, IL-10, IL-12p35, IL-23p19, TNF-α and HERP mRNA in organotypic cultures stimulated by LPS for 6h and 24h in presence or absence of 50μM TFM-C. The levels of mRNA are shown as *n*-fold increase compared with baseline level (-) and normalized to those of the housekeeping gene *Hprt1*. Asterisks indicate significant differences at **P* < 0.05 compared with LPS control by ANOVA test.

doi: 10.1371/journal.pone.0083119.g001




Figure 2. Effect of TFM-C on ER stress, oxidative stress, demyelination and axonal damage in organotypic cerebellar cultures. A) Organotypic cultures were stimulated with LPS for 24h or pre-treated with TFM-C (50μM) for 2h and then stimulated with LPS/TFM-C for 24h. Panel a-b: immunostaining for Iba1 (red) and HERP or iNOS (green). Panel c: immunostaining for NFL (red) and MBP (green); Panel d: immunistaining for total neurofilament-heavy (NFH; red) and non-phosphorylated neurofilament (SMI32; green). In the white box inset are shown axonal spheroids and occurrence of axonal transection (end-bulbs). Scale bar 10μm. B) 10μg of total protein were loaded for HERP, CNPase and iNOS Western blot analysis. Quantification of band intensity was calculated in the graphs below after normalization for total protein loaded. Results are expressed as percentage compared to the LPS only (100%). Error bars indicate the standard error. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ by ANOVA test. C) After 7 DIV organotypic cultures were treated with TFM-C for 2h and then stimulated with 15μg/ml LPS for 6 and 24h. iNOS mRNA expression was analyzed by quantitative PCR. The levels of mRNA are shown as n -fold increase compared with the level of baseline condition (-) and normalized to those of the housekeeping gene *Hprt1*. All values represent the averages of three independent experiments. Error bars indicate the standard error. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ by ANOVA test. D) Percentage of non-phosphorylated neurofilaments with respect to total neurofilaments in cerebellar cultures stimulated for 24h with LPS in presence or absence of TFM-C. Error bars indicate the standard error. * $P < 0.05$ by ANOVA test.

doi: 10.1371/journal.pone.0083119.g002




Figure 3. Effect of TFM-C on HERP and cytokine mRNA and protein production in BV-2 cells. BV2 cells were treated with TFM-C (30 or 50 μ M) for 2h and then stimulated with LPS (1 μ g/ml) for different times in presence or absence of TFM-C. A) Quantification of the kinetics of mRNA production and cytokine secretion (IL-1 β , IL-6 and TNF- α). All values represent the averages of three independent experiments. Lower graphs represent cytokine-specific mRNA quantified by QPCR, while the upper graphs represents amount of secreted cytokine quantified using specific ELISA kits. Asterisks indicate significant differences at * P < 0.05, ** P < 0.01, *** P < 0.001 between TFM-C-treated and LPS-treated cells at each time point using ANOVA test. B) Effect of TFM-C (30 and 50 μ M) on IL-23p19 and HERP mRNAs in BV2 cells stimulated with LPS. The levels of mRNA levels are shown as fold increase. Asterisks indicate significant differences at * P < 0.05 and ** P < 0.01 compared with LPS only using ANOVA test. C) Effect of TFM-C on HERP protein expression. BV2 cells were treated with TFM-C (50 μ M) or pretreated with TFM-C for 2h (30 and 50 μ M) and then stimulated with LPS in presence of TFM-C. Panel a) Immunofluorescence for HERP (green), Iba1 (red) and DAPI (blue) at 12h of LPS/TFM-C or TFM-C treatment. Scale bar 5 μ m. Panel b-c) 10 μ g of total protein were loaded for HERP Western blot analysis. Results were expressed as arbitrary units respect to the control at same time point. Error bars indicate the standard error. * P < 0.05 by ANOVA test. D) Effect of TFM-C treatment (50 μ M) on the viability of BV2 cells. Apoptotic cells were measured by double propidium iodide (PI) and DAPI staining, and the percentage of damaged DNA and condensed chromatin was calculated at 24h of LPS/TFM-C treatment.

doi: 10.1371/journal.pone.0083119.g003

TFM-C induces intracellular retention of TNF-α in BV2 microglia but increases its secretion from primary astrocytes

As demonstrated in Figure 3A, TFM-C reduces secreted levels of IL-1β and TNF-α from BV2 microglial cells. To clarify whether TNF-α was retained intracellularly, an immunofluorescence approach was used to monitor subcellular distribution of TNF-α in the ER/Golgi compartment (in permeabilized cells) or at the plasma membrane (in nonpermeabilized cells). BV2 cells treated with LPS exhibited pronounced intracellular TNF-α staining at 3, 6 and 24 h (Figure 4A, panel a). Co-treatment with TFM-C further enhanced intracellular staining of TNF-α, which was validated by flow cytometry and densitometric analysis (Figure 4A panels a and b, and Figure S3). No significant differences were observed in TNF-α staining at the plasma membrane in nonpermeabilized cells between TFM-C/LPS- and LPS-treated cells (Figure S4). This data suggests that the enhanced levels of secreted TNF-α in TFM-C/LPS-treated organotypic cerebellar cultures (Figure 1A) is unlikely to originate from microglial cell sources. Therefore, we analyzed TNF-α production from isolated primary cortical astrocytes, another LPS-inducible natural source of TNF-α in the Central Nervous System (CNS) [37]. As shown in Figure 4B, astrocyte cultures treated with TFM-C alone displayed marginally increased TNF-α release compared with untreated cultures. However, treatment with LPS/TFM-C induced a 2-fold increase in TNF-α secretion compared with the cultures stimulated with LPS only. This result demonstrates that resident astrocytes in the cerebellar organotypic cultures rather than microglia may constitute the source of TNF-α by TFM-C (Figure 1A).

TFM-C suppresses EAE

Previously we demonstrated that celecoxib inhibited EAE in COX-2-deficient mice [16], associated with reduced MOG-specific Th1 cytokines. Thus, TFM-C treatment might be inferred to exert an effect on autoreactive T cells by suppressing production of these cytokines. We examined the effect of TFM-C on EAE induced by immunization with MOG derived peptide, MOG35-55, in which disease development largely depends on encephalitogenic T cells. The administration of TFM-C reduced the severity of EAE when compared with the control group (Figure 5). The incidence of disease in the control group was 93.8% and TFM-C reduced the incidence to 57.1%. The average day of onset was 15.2±3.1 in control group and 16.4 ±2.5 in the TFM-C-treated group. This result indicates that TFM-C limits the severity of disease showing similar effects to celecoxib [16].

TFM-C suppresses IFN-γ and IL-17 production from MOG-reactive T cells

We next examined the effect of TFM-C on MOG35-55-specific T cell responses by *ex vivo* re-challenge with MOG35-55 peptide 10 days after immunization. The proliferative response to MOG35-55 was slightly reduced in celecoxib-treated mice (Figure 6A). TFM-C exhibited a stronger inhibitory effect on MOG35-55-reactive T cell proliferation, even though the overall effect of TFM-C on proliferation was also




Figure 4. Intracellular localization of TNF-α in BV2 cell line and TNF-α secretion in primary astrocytes. A) BV2 cells were treated with TFM-C (50μM) for 2h and stimulated with LPS (1μg/ml) for 3, 6 and 24h in presence or absence of TFM-C. Panel a) Staining for TNF-α in permeabilized cells. Scale bar 5μm. Panel b) Intracellular localization of TNF-α by flow cytometry. Results are expressed as fold increase compared to the control at the same time point. B) TNF-α release in astrocyte cultures. Astrocytes were treated with TFM-C (30 or 50μM) for 24h or pre-treated with TFM-C for 2h and then stimulated with LPS (1μg/ml) in presence or absence of TFM-C for 24h and then analyzed by ELISA. Error bars indicate the standard deviation. **P*<0.05, ***P*<0.01, ****P*<0.001 by ANOVA test.

doi: 10.1371/journal.pone.0083119.g004




Figure 6. MOG35-55 specific T-cell responses in mice treated with TFM-C. A) Popliteal and inguinal lymph node cells from TFM-C-, celecoxib-treated or control mice were incubated in the presence of MOG35-55 for 48h. Proliferative responses were determined by the uptake of [3 H] thymidine. B and C). The levels of IFN- γ and IL-17 in culture supernatants were measured by ELISA. The data shown are from a single experiment representative of three similar experiments. Error bars represent + SEM of 3 mice per group. * P <0.05 compared with control group, ** P <0.05 compared with both control and celecoxib-treated groups.

doi: 10.1371/journal.pone.0083119.g006




Figure 5. The effect of TFM-C on EAE. Clinical EAE scores of female B6 mice following immunization with MOG35-55. The mice were injected i.p. with 10 μ g/kg TFM-C (closed circles), celecoxib (closed triangles) or vehicle (open squares) every other day starting on the day of immunization. * P <0.05 TFM-C-treated versus vehicle-treated group. Results shown are the mean + SEM of 14-16 mice per group in TFM-C- or vehicle-treated groups and of 5 mice in the celecoxib-treated group. The data shown are pooled data from three similar experiments.

doi: 10.1371/journal.pone.0083119.g005

limited (Figure 6A). Compared to control cells, lymph node cells from MOG35-55-primed TFM-C-treated mice produced significantly lower levels of IFN- γ ; this was also true for lymph

node cells from celecoxib-treated mice albeit to lesser degree (Figure 6B). Furthermore, the level of IL-17 was also significantly reduced in both TFM-C and celecoxib-treated mice compared to that in control mice (Figure 6C). The level of IL-4 was below detection limits (

< 5 pg/ml) (data not shown). These results indicate that TFM-C suppresses MOG35-55-specific T cell proliferation and the production of IL-17 and IFN- γ , and that the suppressive effects of TFM-C on MOG35-55-specific T cell responses are stronger than those of celecoxib.

TFM-C inhibits the production of IL-23 and inflammatory cytokines by dendritic cells

To assess the effect of TFM-C on natural production of IL-12/IL-23, we stimulated Bone Marrow-derived Dendritic Cells (BMDCs) with LPS with or without TFM-C or celecoxib, and measured IL-12 and IL-23 in the culture supernatants. As shown in Figure 7A, IL-23 production was significantly suppressed in the presence of TFM-C. IL-23 suppression was also observed for BMDCs in the presence of celecoxib although the difference did not reach statistical significance. In contrast, neither compound inhibited IL-12 production. To examine the effect on the production of inflammatory cytokines, we stimulated BMDCs with heat-killed *Mtb*, a potent IL-1 stimulator, with or without TFM-C or celecoxib. As shown in Figure 7B, IL-1 β , IL-6 and TNF- α production were inhibited in the presence of TFM-C or celecoxib. These results indicate that TFM-C inhibits the production of IL-23 and inflammatory cytokines by BMDCs.




Figure 7. The effect of TFM-C on cytokine production from BMDCs. BMDCs were incubated in TFM-C, celecoxib or vehicle for 16h and subsequently stimulated with LPS (0.1µg/ml) (A) or heat killed H37Ra Mtb (10µg/ml) (B) in the presence of TFM-C, celecoxib or vehicle. Cytokines were detected by ELISA. IL-12, IL-1β or IL-6 were measured 24h after stimulation. IL-23 and TNF-α were measured 6h after stimulation. The data shown are pooled from two similar experiments. Error bars represent + SEM. * $P<0.05$ control versus TFM-C celecoxib-treated group, ** $P<0.05$ control versus TFM-C -treated group.

doi: 10.1371/journal.pone.0083119.g007

Discussion

In this study, we have tested a non-coxib analogue of celecoxib, TFM-C, both in a model of neuroinflammation consisting of organotypic cultures challenged with LPS [32] and in EAE. The former model recapitulates several events that occur during brain inflammation, including microglia activation followed by cytokine release and oxidative stress, demyelination and axonal damage and permits to study the effect and the mechanism of new treatments for neuroinflammatory disorders [31,32]. Of note, TFM-C significantly decreased axonal damage and oxidative stress in organotypic cultures associated with suppression of IL-1β, IL-12 and IL-17 secretion but enhanced that of TNF-α and RANTES. Similarly to celecoxib in EAE, TFM-C reduced infiltration in CNS, demyelination and production of IFN-γ and IL-17. Further analysis showed that astrocytes cultures treated with TFM-C increased TNF-α release. Moreover, we observed

a 2-fold increase in the TNF-α secretion when the astrocytes were co-treated with LPS/TFM-C for 24 hours compared with the cultures stimulated with LPS only. In contrast, in the BV2 microglia cell line, TFM-C suppressed secreted TNF-α protein levels. An explanation for these opposite effects should be sought in the differential response of astrocytes and microglia to modulation of intracellular calcium homeostasis through selectively inhibiting ER Ca^{2+} -ATPases by celecoxib or TFM-C [5,38]. Astrocytes possess an intracellular Ca^{2+} -dependent excitability leading to glutamate release [39–44]. For example, A23187, a Ca^{2+} -dependent ER stressor, induces elevation of calcium levels, thus increasing glutamate release [45]. In addition, stimulation of astrocytes by glutamate or ATP induces a glutamatergic response accompanied by TNF-α release [46]. However, ionomycin, another Ca^{2+} -dependent ER stressor, does not induce cytokine release in microglia, indicating that in microglia Ca^{2+} perturbation is not sufficient to induce cytokines secretion [47]. These data suggest that the resident astrocytes

and microglia in our cerebellar organotypic cultures respond differentially to Ca^{2+} perturbation by TFM-C in terms of TNF- α secretion.

We also observed a significant increase of RANTES levels in organotypic cultures treated with TFM-C. RANTES is a chemokine that promotes the recruitment and activation of inflammatory cells such as monocytes, lymphocytes, mast cells and eosinophils [48-51]. RANTES also attracts memory T cells, promoting the formation of mononuclear infiltrates characteristic of MS [49,52]. Moreover, it has been described that astrocytes can generate RANTES after stimulation with TNF- α , IL-1 β and IFN- γ . Actually, RANTES can be induced only by TNF- α alone in rat primary astrocytes [53].

The role of TNF- α in the pathogenesis of inflammatory demyelinating disease of the central nervous system has been demonstrated in rodents [54] and in humans [55-57]. Transgenic mice that constitutively express TNF- α in the CNS can trigger the development of a chronic inflammatory demyelinating disease [58]. TNF- α is synthesized as a transmembrane precursor protein (tmTNF) and its cytoplasmic tail is cleaved by the TNF- α -converting enzyme (TACE) to release a soluble TNF- α (sTNF). These two forms of TNF- α interact with the receptors, tumor necrosis factor 1 (TNFR1) and 2 (TNFR2). TNFR1 is expressed in all cell types and is preferentially bound by sTNF whereas TNFR2 is expressed by endothelial cells and immune cells and especially bound by tmTNF [59]. The activation of TNFR1 can induce either activation of NF κ B or apoptosis via caspase 8 and 3 [60]. The binding to TNFR2 induces proinflammatory and survival signaling pathways [61]. Comparison of TNFR1 and TNFR1/TNFR2 knockout and wild-type mice, shows that EAE symptoms were milder or absent in the knockout animals. In contrast, in TNFR2-deficient mice the symptoms were enhanced and associated with high inflammation and demyelination [62,63]. Remyelinated function was conferred to TNFR2 whereas demyelination to TNFR1 [64]. Recently, we have shown that demyelination was significantly attenuated in cerebellar cultures challenged with LPS pretreated with Fc-TNFR1 recombinant protein [32]. In particular, we found that myelin damage and oligodendrocyte loss were promoted by pro-inflammatory cytokines such as TNF- α . Probably, the observation that the TFM-C treatment had no effect on demyelination in organotypic culture model could be explained by increased astrocytic TNF- α , that in turn induces TNFR1 activation. Moreover, immune cells expressing TNFR2 are lacking in organotypic cultures. In contrast, in the same model TFM-C exerts beneficial effects restoring oxidative stress and axonal damage induced by LPS.

In the EAE model, although the treatment with TFM-C failed to completely inhibit the development of EAE, TFM-C significantly reduced the severity of the disease decreasing the incidence from 93.8% to 57.1%. Moreover, TFM-C suppressed the production of IL-23 and inflammatory cytokines, IL-1 β , IL-6 and TNF- α from dendritic cells and this suppressive effect was strong enough to decrease the subsequent production of IL-17 and IFN- γ from lymph node cells upon stimulation with MOG. The differential effects observed on IL-23 inhibition by celecoxib vs TFM-C suggest a beneficial effect of the latter via

inhibition of the Th17 responses. In addition to the suppression of IL-23, blockage of IL-6 and IL-1 β , two cytokines that affect development of Th17 cells, would also contribute to the suppression of IL-17 [65,66]. TNF- α , IL-1 β and IL-6 can increase the permeability of the blood-brain barrier (BBB) [67]. IL-6 induces leukocyte chemoattraction to the endothelium, as well as lymphocyte activation. IL-6 is found in high concentrations in active MS lesions [68,69]. In EAE, IL-6 induction is found in the spinal cord [70]. The detrimental role of IL-6 in this model, associated with BBB permeability, is evidenced in IL-6-deficient mice that are resistant to the pathophysiological alterations [71]; on the other hand, mice overexpressing astrocytic IL-6 showed indeed breakdown of the BBB [72]. Moreover, the inhibition of IL-6 in BMDCs and macrophages [17] treated with TFM-C might suggest that the beneficial effect of TFM-C in EAE can depend on its ability to reduce BBB permeability.

The different effect of TFM-C observed in CNS-derived cells versus lymph node-derived cells may reside in incomplete penetration of TFM-C into CNS. In the *in vivo* system, TFM-C may exert a beneficial effect on peripheral cells, reducing proliferation and pro-inflammatory cytokine secretion, thus ameliorating disease severity. In contrast, when CNS cells are exposed directly to TFM-C, such as in the organotypic, astrocyte or microglia cultures, these cells may respond to Ca^{2+} perturbation differentially by either increasing or decreasing pro-inflammatory cytokine secretion. However, it remains to be determined whether TFM-C penetrates into the intact CNS following i.p. injection. If not, the main cellular mediators of its cytokine-modulating effects are likely to be the peripheral immune cells. This could explain why TFM-C failed to inhibit completely the development of EAE. In summary, we have described a new drug with potential beneficial effects for MS. The therapeutic niche covered by TFM-C may include beneficial effects in both innate and adaptive immunity, which is incompletely covered by current therapies [73]. In this sense, the therapy can be defined as acting in the interface between immunomodulation and neuroprotection. Thus, design of further non-coxib celecoxib analogues with improved activity profiles may be warranted.

Supporting Information

Figure S1. Effect of TFM-C on MHCII protein expression. Organotypic cultures were stimulated with LPS for 24h or pre-treated with TFM-C (50 μ M) for 2h and then stimulated with LPS/TFM-C for 24h. Immunofluorescence for Iba1 (red) and MHCII (green) was performed. White boxes show higher magnifications of merged images. Scale bar 50 μ m. (TIF)

Figure S2. Effect of TFM-C on expression of genes belonging to Unfolded Protein Response (U), Ubiquitination (Ub) and Autophagy (A) pathways in HEK-293 cells and BV2 cells. A) HEK-293 cells were treated with TFM-C (50 μ M) for 12h and U, Ub and A PCR arrays were performed. The genes represented in the table are those with a fold increase higher than 2.5 compared with control samples

and are ranked according to expression level (high to low). B) HEK-293 cells were treated with TFM-C (50 μ M) for different times and RT-QPCR was performed. Selected genes (*PARK2*, *FBXO4*, *RAB24*, *MAP1LCB3*, *HERP* and *ARMET*) were validated in three independent experiments. The levels of mRNA are shown as $2^{-\Delta\Delta Ct}$ compared with the level of baseline condition (-) and normalized with the housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase. Asterisks indicate significant differences at * $P < 0.05$ by Student's test. C) 20 μ g of total protein were loaded for *PARK2*, *FBXO4*, *RAB24*, *MAP1LCB3*, *HERP*, *ARMET* and tubulin Western blot analysis. D) BV2 cells were pre-treated with TFM-C (30 or 50 μ M) for 2h, then stimulated with LPS for different times and 10 μ g of total protein were loaded for Western blot analysis. Results were expressed as arbitrary units compared to the control at same time point. All values represent the averages of three independent experiments. Error bars indicate the standard error. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ by ANOVA test. (TIF)

Figure S3. Quantification of intracellular TNF- α in BV2 cell line. The cells were treated as described in Figure 5 and the fluorescence intensity was analyzed via densitometry using a fluorescence microscope by calculating mean grey value (pixel intensity) normalized by fixed area (ROI=Region Of Interest; Image J Software). For each condition ten cells/field were analyzed for a total of 4 fields and 40 cells. Error bars indicate the standard error. (TIF)

Figure S4. Quantification of TNF- α in plasma membrane of BV2 cell line. BV2 cells were treated with TFM-C (50 μ M) for 2h and stimulated with LPS (1 μ g/ml) for 3, 6 and 24h in presence or absence of TFM-C. The cells were fixed with PFA and stained for TNF- α . A) Fluorescence intensity was analyzed by densitometry calculating mean pixel intensity normalized by

ROI fixed area (Image J Software). For each condition ten cells/field were analyzed for a total of 4 fields and 40 cells. Error bars indicate the standard error. B) Staining for TNF- α in non-permeabilized cells. Scale bar 5 μ m. (TIF)

Figure S5. Normalization of protein expression. BV2 cells were treated with TFM-C (50 μ M) for different times and 10 μ g of total protein were loaded in Stain-free Precast Gels and then transferred to nitrocellulose membrane. A) Total protein was visualized by UV excitation. B) Tubulin protein expression analyzed by Western blot. C) Quantification of HERP band intensity normalized with total protein loaded. D) Quantification of HERP band intensity normalized with Tubulin protein. The values represent the averages of three independent experiments. Significant differences at * $P < 0.05$ and ** $P < 0.01$ compared with control (0h) by Student's test. (TIF)

Acknowledgements

Technical and human support provided by SGIker (UPV/EHU, MICINN, GV/EJ, ESF) is gratefully acknowledged for cytometry and confocal microscopy.

Author Contributions


Performed the experiments: AdP AC AW. Analyzed the data: AdP AC IA TY PV SM KV. Contributed reagents/materials/analysis tools: KV PV SM TY. Wrote the manuscript: AdP AC SM KV. Carried out the microscopy, molecular studies, organotypic cultures, EAE model and performed the statistical analysis: AdP AC. Performed astrocytes cultures: AW. Participated in the design and interpretation of the study: AdP AC IA PV SM TY KV. Read and approved the final manuscript: AdP AC IA AW PV SM TY KV.

References

- Shi S, Klotz U (2008) Clinical use and pharmacological properties of selective COX-2 inhibitors. *Eur J Clin Pharmacol* 64: 233-252. doi: 10.1007/s00228-007-0400-7. PubMed: 17999057.
- DeWitt DL (1999) Cox-2-selective inhibitors: the new super aspirins. *Mol Pharmacol* 55: 625-631. PubMed: 10101019.
- Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G (2001) COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. *FASEB J* 15: 2742-2744. PubMed: 11606477.
- Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP et al. (2004) 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. *Cancer Res* 64: 1444-1451. doi: 10.1158/0008-5472.CAN-03-2396. PubMed: 14973075.
- Alloza I, Baxter A, Chen Q, Matthiesen R, Vandenbroeck K (2006) Celecoxib inhibits interleukin-12 alpha/beta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum. *Mol Pharmacol* 69: 1579-1587. doi:10.1124/mol.105.020669. PubMed: 16467190.
- McLaughlin M, Alloza I, Quoc HP, Scott CJ, Hirabayashi Y et al. (2010) Inhibition of secretion of interleukin (IL)-12/23 family cytokines by 4-trifluoromethyl-celecoxib is coupled to degradation via the endoplasmic reticulum stress protein HERP. *J Biol Chem* 285: 6960-6969. doi: 10.1074/jbc.M109.056614. PubMed: 20054003.
- Vandenbroeck K, Alloza I, Brehmer D, Billiau A, Proost P et al. (2002) The conserved helix C region in the superfamily of interferon-gamma / interleukin-10-related cytokines corresponds to a high-affinity binding site for the HSP70 chaperone DnaK. *J Biol Chem* 277: 25668-25676. doi:10.1074/jbc.M202984200. PubMed: 11970958.
- Vandenbroeck K, Martens E, Alloza I (2006) Multi-chaperone complexes regulate the folding of interferon-gamma in the endoplasmic reticulum. *Cytokine* 33: 264-273. doi:10.1016/j.cyt.2006.02.004. PubMed: 16574426.
- McLaughlin M, Vandenbroeck K (2011) The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery? *Br J Pharmacol* 162: 328-345. doi:10.1111/j.1476-5381.2010.01064.x. PubMed: 20942857.
- Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS (2002) The cyclooxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca²⁺-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. *Biochem J* 366: 831-837. PubMed: 12076251.
- Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM et al. (2008) Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. *Cancer Res* 68: 843-851. doi:10.1158/0008-5472.CAN-07-5555. PubMed: 18245486.
- Okada T, Yoshida H, Akazawa R, Negishi M, Mori K (2002) Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein

- response. *Biochem J* 366: 585–594. doi:10.1042/BJ20020391. PubMed: 12014989.
13. Oyadomari S, Mori M (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. *Cell Death Differ* 11: 381–389. doi:10.1038/sj.cdd.4401373. PubMed: 14685163.
 14. Ni J, Shu YY, Zhu YN, Fu YF, Tang W et al. (2007) COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. *J Neuroimmunol* 186: 94–103. doi:10.1016/j.jneuroim.2007.03.012. PubMed: 17442406.
 15. Reder AT, Thapar M, Sapugay AM, Jensen MA (1994) Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. *J Neuroimmunol* 54: 117–127. doi:10.1016/0165-5728(94)90238-0. PubMed: 7523442.
 16. Miyamoto K, Miyake S, Mizuno M, Oka N, Kusunoki S et al. (2006) Selective COX-2-inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. *Brain* 129: 1984–1992. doi:10.1093/brain/awl170. PubMed: 16835249.
 17. Chiba A, Mizuno M, Tomi C, Tajima R, Alloza I, et al. (2012) A 4-trifluoromethyl analogue of celecoxib inhibits arthritis by suppressing innate immune cell activation. *Arthritis Res Ther* 14: R9.
 18. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B et al. (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ* 342: c7086. doi:10.1136/bmj.c7086. PubMed: 21224324.
 19. Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT et al. (2009) Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. *Circ Cardiovasc Qual Outcomes* 2: 155–163. doi:10.1161/CIRCOUTCOMES.108.805689. PubMed: 20031832.
 20. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J et al. (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. *Circulation* 117: 2104–2113. doi:10.1161/CIRCULATIONAHA.108.764530. PubMed: 18378608.
 21. Feng GS, Ma JL, Wong BC, Zhang L, Liu WD, et al. (2008) Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. *World J Gastroenterol* 14: 4535–4539.
 22. Haag MDM, Bos MJ, Hofman A, Koudstaal PJ, Breteler MMB et al. (2008) Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. *Arch Intern Med* 168: 1219–1224. doi:10.1001/archinte.168.11.1219. PubMed: 18541831.
 23. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. *J Clin Invest* 116: 4–15. PubMed: 16395396.
 24. Pidgeon GP, Tamosiuniene R, Chen G, Leonard I, Belton O et al. (2004) Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. *Circulation* 110: 2701–2707. doi:10.1161/01.CIR.0000145613.01188.0B. PubMed: 15492320.
 25. Buerkle MA, Lehrer S, Sohn H-Y, Conzen P, Pohl U et al. (2004) Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. *Circulation* 110: 2053–2059. doi:10.1161/01.CIR.0000143234.51796.A9. PubMed: 15451781.
 26. Stoppini L, Buchs PA, Muller D (1991) A simple method for organotypic cultures of nervous tissue. *J Neurosci Methods* 37: 173–182. doi:10.1016/0165-0270(91)90128-M. PubMed: 1715499.
 27. Dusart I, Airaksinen MS, Sotelo C (1997) Purkinje cell survival and axonal regeneration are age dependent: an in vitro study. *J Neurosci* 17: 3710–3726. PubMed: 9133392.
 28. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F (1990) Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. *J Neuroimmunol* 27: 229–237. doi:10.1016/0165-5728(90)90073-V. PubMed: 2110186.
 29. McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. *J Cell Biol* 85: 890–902. doi:10.1083/jcb.85.3.890. PubMed: 6248568.
 30. Fan LW, Tien LT, Mitchell HJ, Rhodes PG, Cai Z (2008) Alpha-phenyl-n-tert-butyl-nitron ameliorates hippocampal injury and improves learning and memory in juvenile rats following neonatal exposure to lipopolysaccharide. *Eur J Neurosci* 27: 1475–1484.
 31. Kim JY, Shen S, Dietz K, He Y, Howell O et al. (2010) HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. *Nat Neurosci* 13: 180–189. doi:10.1038/nn.2471. PubMed: 20037577.
 32. Di Penta A, Moreno B, Reix S, Fernandez-Diez B, Villanueva M et al. (2013) Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. *PLOS ONE* 8: e54722. doi:10.1371/journal.pone.0054722.
 33. Sherwin C, Fern R (2005) Acute lipopolysaccharide-mediated injury in neonatal white matter glia: role of TNF-alpha, IL-1beta, and calcium. *J Immunol* 175: 155–161. PubMed: 15972642.
 34. Coleman M (2005) Axon degeneration mechanisms: commonality amid diversity. *Nat Rev Neurosci* 6: 889–898. doi:10.1038/nrn1788. PubMed: 16224497.
 35. Wheeler MC, Rizzi M, Sasik R, Almanza G, Hardiman G, et al. (2008) KDEL-retained antigen in B lymphocytes induces a proinflammatory response: a possible role for endoplasmic reticulum stress in adaptive T cell immunity. *J Immunol* 181: 256–264.
 36. Ron D, Habener JF (1992) CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. *Genes Dev* 6: 439–453. doi:10.1101/gad.6.3.439. PubMed: 1547942.
 37. Chung IY, Benveniste EN (1990) Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. *J Immunol* 144: 2999–3007.
 38. Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS (2002) The cyclooxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. *Biochem J* 366: 831–837. PubMed: 12076251.
 39. Cornell-Bell AH, Finkbeiner SM, Cooper MS, Smith SJ (1990) Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling. *Science* 247: 470–473.
 40. Charles AC, Merrill JE, Dirksen ER, Sanderson MJ (1991) Inter-cellular signaling in glial cells: calcium waves and oscillations in response to mechanical stimulation and glutamate. *Neuron* 6: 983–992. doi:10.1016/0896-6273(91)90238-U. PubMed: 1675864.
 41. Parpura V, Basarsky TA, Liu F, Jeffinija K, Jeffinija S et al. (1994) Glutamate-mediated astrocyte-neuron signalling. *Nature* 369: 744 – 747. doi:10.1038/369744a0. PubMed: 7911978.
 42. Pasti L, Volterra A, Pozzan T, Carmignoto G (1997) Intracellular calcium oscillations in astrocytes: a highly plastic, bidirectional form of communication between neurons and astrocytes in situ. *J Neurosci* 17: 7817–7830. PubMed: 9315902.
 43. Newman EA, Zahs KR (1997) Calcium waves in retinal glial cells. *Science* 275: 844–857. doi:10.1126/science.275.5301.844. PubMed: 9012354.
 44. Bezzi P, Carmignoto G, Pasti L, Vesce S, Rossi D et al. (1998) Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. *Nature* 391: 281–285. doi:10.1038/34651. PubMed: 9440691.
 45. Innocenti B, Parpura V, Haydon PG (2000) Imaging extracellular waves of glutamate during calcium signaling in cultured astrocytes. *J Neurosci* 20: 1800–1808. PubMed: 10684881.
 46. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D et al. (2001) CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. *Nat Neurosci* 4: 702–710. doi:10.1038/89490. PubMed: 11426226.
 47. Hoffmann A, Kann O, Ohlemeyer C, Hanisch UK, Kettenmann H (2003) Elevation of basal intracellular calcium as a central element in the activation of brain macrophages (microglia): suppression of receptor-evoked calcium signaling and control of release function. *J Neurosci* 23: 4410–4419.
 48. Meurer R, Van Riper G, Feeney W, Cunningham P, Hora D Jr et al. (1993) Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8. *J Exp Med* 178: 1913–1921. doi:10.1084/jem.178.6.1913. PubMed: 7504053.
 49. Schall TJ, Bacon K, Toy KJ, Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. *Nature* 347: 669–671. doi:10.1038/347669a0. PubMed: 1699135.
 50. Conti P, Reale M, Barbacane RC, Letourneau R, Theoharides TC (1998) Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W/WV mice. *FASEB J* 12: 1693–1700. PubMed: 9837859.
 51. Das AM, Ajubor MN, Flower RJ, Perretti M, McColl SR (1999) Contrasting roles for RANTES and macrophage inflammatory protein-1 alpha (MIP-1 alpha) in a murine model of allergic peritonitis. *Clin Exp Immunol* 117: 223–229. doi:10.1046/j.1365-2249.1999.00978.x. PubMed: 10444251.
 52. Weber C, Weber KS, Klier C, Gu S, Wank R et al. (2001) Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of

- monocytes and T(H)1-like/CD45RO(+) T cells. *Blood* 97: 1144–1146. doi:10.1182/blood.V97.4.1144. PubMed: 11159551.
53. Barnes DA, Huston M, Holmes R, Benveniste EN, Yong VW et al. (1996) Induction of RANTES expression by astrocytes and astrocytoma cell lines. *J Neuroimmunol* 71: 207–214. doi:10.1016/S0165-5728(96)00154-3. PubMed: 8982121.
 54. Selmaj K, Raine CS, Cross AH (1991) Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. *Ann Neurol* 30: 694–700. doi:10.1002/ana.410300510. PubMed: 1722388.
 55. Baker D, Butler D, Scallion BJ, O'Neill JK, Turk JL et al. (1994) Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. *Eur J Immunol* 24: 2040–2048. doi:10.1002/eji.1830240916. PubMed: 8088324. Available online at: doi:10.1002/eji.1830240916 Available online at: PubMed: 8088324
 56. Hofman FM, Hinton DR, Johnson K, Merrill JE (1989) Tumor necrosis factor identified in multiple sclerosis brain. *J Exp Med*, 170: 607–612. doi:10.1084/jem.170.2.607. PubMed: 2754393.
 57. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. *N Engl J Med* 325: 467–472. doi:10.1056/NEJM199108153250704. PubMed: 1852181.
 58. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. *Proc Natl Acad Sci U S A* 92: 11294–11298. doi:10.1073/pnas.92.24.11294. PubMed: 7479982.
 59. Grell M, Wajant H, Zimmermann G, Scheurich P (1998) The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. *Proc Natl Acad Sci U S A* 95: 570–575. doi:10.1073/pnas.95.2.570. PubMed: 9435233.
 60. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. *Pharmacol Ther* 117: 244–279. doi:10.1016/j.pharmthera.2007.10.001. PubMed: 18155297.
 61. Yang L, Lindholm K, Konishi Y, Li R, Shen Y (2002) Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. *J Neurosci* 22: 3025–3032. PubMed: 11943805.
 62. Suvannavejh GC, Lee HO, Padilla J, Dal Canto MC, Barrett TA et al. (2000) Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG (35–55)-induced experimental autoimmune encephalomyelitis. *Cell Immunol* 205: 24–33. doi:10.1006/cimm.2000.1706. PubMed: 11078604.
 63. Kassiotis G, Kollias G (2001) Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. *J Exp Med* 193: 427–434. doi:10.1084/jem.193.4.427. PubMed: 11181695.
 64. Caminero A, Comabella M, Montalban X (2011) Tumor necrosis factor alpha (TNF- α), anti-TNF- α and demyelination revisited: an ongoing story. *J Neuroimmunol* 234: 1–6. doi:10.1016/j.jneuroim.2011.03.004. PubMed: 21474190.
 65. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. *Nature* 441: 235–238. doi:10.1038/nature04753. PubMed: 16648838.
 66. Veldhoen M, Hocking RJ, Atkins CH, Locksley RM, Stockinger B (2006) TGF β in the context of an inflammatory cytokine milieu supports de novo differentiation of mIL-17-producing cells. *Immunity* 24: 179–189. doi:10.1016/j.immuni.2006.01.001. PubMed: 16473830.
 67. de Vries HE, Blom-Rosemalen MC, van Oosten M, de Boer AG, van Berkel TJ et al. (1996) The influence of cytokines on the integrity of the blood-brain barrier in vitro. *J Neuroimmunol* 64: 37–43. doi:10.1016/0165-5728(95)00148-4. PubMed: 8598388.
 68. Cannella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. *Ann Neurol* 37: 424–435. doi:10.1002/ana.410370404. PubMed: 7536402.
 69. Woodroffe MN, Cuzner ML (1993) Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. *Cytokine* 5: 583–588. doi:10.1016/S1043-4666(05)80008-0. PubMed: 8186370.
 70. Agnello D, Bigini P, Villa P, Mennini T, Cerami A et al. (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. *Brain Res* 952: 128–134. doi:10.1016/S0006-8993(02)03239-0. PubMed: 12363412.
 71. Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A (1998) IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. *Eur J Immunol* 28: 2178–2187. doi:10.1002/(SICI)1521-4141(199807)28:07. PubMed: 9692887.
 72. Brett FM, Mizisin AP, Powell HC, Campbell IL (1995) Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. *J Neuropathol Exp Neurol* 54: 766–775. doi:10.1097/00005072-199511000-00003. PubMed: 7595649.
 73. Castro-Borrero W, Graves D, Frohman TC, Bates Flores A, Hardeman P et al. (2012) Current and emerging therapies in multiple sclerosis: a systematic review. *Ther Adv Neurol Disord* 5: 205–220. doi:10.1177/1756285612450936. PubMed: 22783370.



The importance of CCR4 and CCR6 in experimental autoimmune encephalomyelitis

Kota Moriguchi ^{a,b}, Katsuichi Miyamoto ^{c,*}, Noriko Tanaka ^c, Osamu Yoshie ^d, Susumu Kusunoki ^c

^a Division of Neurology, Department of Internal Medicine 3, National Defense Medical College, Tokorozawa, Japan

^b Middle Army Medical Unit, Japan Ground Self Defense Force, Itami, Japan

^c Department of Neurology, Kinki University School of Medicine, Osaka-Sayama, Japan

^d Department of Microbiology, Kinki University School of Medicine, Osaka-Sayama, Japan

ARTICLE INFO

Article history:

Received 4 October 2012

Received in revised form 19 January 2013

Accepted 11 February 2013

Keywords:

Experimental autoimmune encephalomyelitis

Chemokine receptor

Th17

CCR6

CCR4

ABSTRACT

Chemokine receptors (CCRs) play important roles in the pathogenesis of immune-mediated diseases, as well as in normal immune response. We examined the role of CCR6 and CCR4 in experimental autoimmune encephalomyelitis (EAE) by using CCR6^{-/-}CCR4^{-/-} double knockout (DKO) and single knockout mice. DKO mice developed less severe EAE and presented repressed recall response in the induction phase, especially in the activity of T helper 17 (Th17) cells. CCR6 expression in central nervous system (CNS)-infiltrated cells was diminished in DKO. Our results suggest that CCR6 and CCR4 were involved in a more rapid progression of EAE and that their regulation might be a therapeutic target of human inflammatory demyelinating diseases.

© 2013 Elsevier B.V. All rights reserved.

1. Introduction

C-C chemokines and chemokine receptors (CCRs) play important roles in the immune response by regulating leukocyte migration, infiltration to organs, lymphocyte differentiation, and cytokine production. Chemokine receptors have become clinical therapeutic targets. An anti-CCR4 antibody is now applied to patients with adult T cell lymphoma/leukemia and peripheral T cell lymphoma (Ishida and Ueda, 2006).

Experimental autoimmune encephalomyelitis (EAE) is a T helper 1/17 (Th1/Th17)-mediated autoimmune disease that can be induced in experimental animals as a disease model of human multiple sclerosis (Domingues et al., 2010). Many studies have been performed to evaluate the role of chemokine receptors in EAE, including CCR6 and CCR4 (Elhofy et al., 2009; Liston et al., 2009; Reboldi et al., 2009; Villares et al., 2009; Forde et al., 2011).

CCR4 is expressed in Th2/Th17 and considered to contribute to Th2 activation (Koelink et al., 2011). In atopic dermatitis patients, the number of CCR4⁺ memory T cells is increased in the peripheral blood and correlated with clinical severity (Nakatani et al., 2001). On the other hand, Forde et al. reported that CCR4 knockout mice

developed less severe EAE (Forde et al., 2011). CCR6 is expressed in Th17 and dendritic cells and considered to regulate Th1/Th17 differentiation (Koelink et al., 2011). Indeed, Reboldi et al. and Liston et al. reported that CCR6 knockout mice developed less severe EAE and showed repressed recall response (Liston et al., 2009; Reboldi et al., 2009). However, Villares et al. reported that CCR6 knockout mice developed a severe course of EAE and Elhofy reported that CCR6 knockout mice failed to control the relapsing phase of EAE (Elhofy et al., 2009; Villares et al., 2009). The clinical relevance between inflammatory demyelinating disease and chemokine receptors is still controversial. Here, we examined the role of CCR6 and CCR4 in EAE, two major chemokine receptors expressed in pathogenetic Th17 in EAE (Aranami and Yamamura, 2008), using CCR6^{-/-}CCR4^{-/-} double knockout (DKO) mice, in addition to CCR6^{-/-} and CCR4^{-/-} single knockout mice.

2. Materials and methods

2.1. Mice

Mice used for this study were maintained in a specific pathogen-free (SPF) condition in the animal facility of the Kinki University School of Medicine. DKO mice were generated by mating C57BL/6-CCR6^{+/-} mice and C57BL/6-CCR4^{+/-} mice. CCR6^{-/-} and CCR4^{-/-} mice were originally obtained from Dr. Yoshie. Mice were backcrossed at least 8 generations onto C57BL/6 background. Genotyping of DKO mice was performed by polymerase chain reaction (PCR) as described elsewhere. All experiments were performed according to the guidelines of the institutional ethics committee. All mice used in the experiments were aged 8 to 16 weeks.

Abbreviations: 4KO, CCR4 knockout; 6KO, CCR6 knockout; DKO, CCR6^{-/-}CCR4^{-/-} double knockout; EAE, experimental autoimmune encephalomyelitis; MS, multiple sclerosis; MOG, myelin oligodendrocyte glycoprotein; PCR, polymerase chain reaction; WT, wild type.

* Corresponding author at: Department of Neurology, Kinki University School of Medicine, Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. Tel.: +81 72 366 0221x3552; fax: +81 72 368 4846.

E-mail address: miyamoto@med.kindai.ac.jp (K. Miyamoto).